Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Julphar
Mallinckrodt
Baxter
US Army
Express Scripts
Moodys
Queensland Health

Generated: November 18, 2018

DrugPatentWatch Database Preview

Taro Pharm Inds Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for TARO PHARM INDS LTD, and when can generic versions of TARO PHARM INDS LTD drugs launch?

TARO PHARM INDS LTD has nineteen approved drugs.

There are two US patents protecting TARO PHARM INDS LTD drugs.

Summary for Taro Pharm Inds Ltd
US Patents:2
Tradenames:11
Ingredients:9
NDAs:19

Drugs and US Patents for Taro Pharm Inds Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm Inds Ltd DESLORATADINE desloratadine SOLUTION;ORAL 202592-001 Jun 30, 2015 AA RX No No ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd ACETAMINOPHEN acetaminophen SUPPOSITORY;RECTAL 018337-001 Approved Prior to Jan 1, 1982 OTC Yes Yes ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd HYDROCORTISONE AND ACETIC ACID acetic acid, glacial; hydrocortisone SOLUTION/DROPS;OTIC 088759-001 Mar 4, 1985 AT RX No No ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd HYDROCORTISONE hydrocortisone CREAM;TOPICAL 086155-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd TOPICORT desoximetasone CREAM;TOPICAL 017856-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TARO PHARM INDS LTD drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Spray 0.25% ➤ Subscribe 2013-12-18
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 2011-03-16

Supplementary Protection Certificates for Taro Pharm Inds Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/005 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C/GB10/012 United Kingdom ➤ Sign Up PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C/GB01/012 United Kingdom ➤ Sign Up PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
01C/045 Belgium ➤ Sign Up PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
00085 Netherlands ➤ Sign Up PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Cantor Fitzgerald
Boehringer Ingelheim
Dow
Fuji
US Army
Accenture
Covington
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.